Patents Assigned to Aldeyra Therapeutics, Inc.
  • Methotrexate treatment methods
    Patent number: 11911385
    Abstract: The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: February 27, 2024
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Stephen Gitu Machatha, Dean Eliott, Tomasz Stryjewski
  • Deuterated compounds and uses thereof
    Patent number: 11845722
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: December 19, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Ophthalmic formulations and uses thereof
    Patent number: 11786518
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: October 17, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: David Clark, Susan Macdonald, Stephen Gitu Machatha, Lise Lund Kjems
  • Toxic aldehyde related diseases and treatment
    Patent number: 11771664
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: October 3, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Compositions and methods of treating retinal disease
    Patent number: 11724987
    Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 15, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Thomas A. Jordan, John E. Dowling, John Clifford Chabala
  • Toxic aldehyde related diseases and treatment
    Patent number: 11701331
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: July 18, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Treatment of inflammatory disorders
    Patent number: 11583529
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 21, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Susan Macdonald, Adna Halilovic
  • Deuterated compounds and uses thereof
    Patent number: 11459300
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: October 4, 2022
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Polymorphic compounds and uses thereof
    Patent number: 11312692
    Abstract: The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: April 26, 2022
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Stephen Gitu Machatha, Jonathan J. Loughrey, Hannah Ruth McLachlan, Gregor Sneddon
  • Formulations for treatment of dry eye disease
    Patent number: 11197821
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: December 14, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: David Clark, Todd Brady, Susan Macdonald, Stephen Gitu Machatha
  • Combination treatment of ocular inflammatory disorders and diseases
    Patent number: 11129823
    Abstract: The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 28, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young
  • Deuterated compounds and uses thereof
    Patent number: 11046650
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 29, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Treatment of inflammatory disorders
    Patent number: 11040039
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: June 22, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Susan Macdonald, Adna Halilovic
  • Toxic aldehyde related diseases and treatment
    Patent number: 11007157
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: May 18, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Compositions and methods of treating retinal disease
    Patent number: 10913722
    Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: February 9, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Thomas A. Jordan, John E. Dowling, John Clifford Chabala
  • Toxic aldehyde related diseases and treatment
    Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Deuterated compounds and uses thereof
    Patent number: 10550085
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 4, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 10543181
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 28, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Treatment of allergic eye conditions with cyclodextrins
    Patent number: 10426790
    Abstract: The present disclosure provides methods of treating eye allergies and allergic conjunctivitis with cyclodextrin. Ophthalmic compositions of cyclodextrin for topical administration are also provided.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 1, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Scott Young, Todd Brady, Stephen Gitu Machatha, David Clark, Susan Macdonald
  • Polymorphic compounds and uses thereof
    Patent number: 10414732
    Abstract: The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions, in which aldehyde toxicity is implicated in the pathogenesis, by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 17, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Amanda Buist, Eden Fucci, Stephen G. Machatha, Osama Suleiman, Kate Wittering